IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy
Innovative use of geofencing technology boosts enrollment at select sites POTOMAC, MD / ACCESSWIRE / January 8, 2025 / (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today that its ...
IGC Gains on Word of Alzheimer’s Treatment
IGC Pharma, Inc. (NYSE:IGC) shares made small progress Wednesday, on word its ongoing Phase 2 trial for agitation in Alzheimer's disease has been officially named CALMA (Calming Agitation in Alzheimer ...
IGC Pharma, Inc.: IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy
Innovative use of geofencing technology boosts enrollment at select sites POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced to ...
Axsome reports mixed results for Alzheimer's agitation drug
Axsome Therapeutics (AXSM) stock fell 12% Monday after the company reported mixed Phase 3 results for its drug AXS-05 in the ...
BioSpace6d
Axsome Posts Mixed Phase III Data in Alzheimer’s Agitation, Plans FDA Filing
With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval ...
Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation
ACCORD-2 Phase 3 trial in Alzheimer’s disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse)ACCORD-2 Phase 3 ...
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
Axsome Therapeutics, Inc. (NASDAQ:AXSM) released data from ACCORD-2, ADVANCE-2, and long-term safety trials AXS-05 ...
STAT9d
Axsome to send Alzheimer’s disease drug to FDA, despite mixed Phase 3 results
Axsome Therapeutics said it would submit its Alzheimer’s disease treatment for FDA approval despite mixed results from two ...
MedCity News9d
Axsome Aims for FDA Filing in Alzheimer’s Agitation Despite Mixed Bag of Phase 3 Data
Agitation caused by Alzheimer’s disease currently has one FDA-approved therapy, but that drug brings serious safety risks. An Axsome Therapeutics drug has mixed results from its latest slate of ...
Analysts see buying opportunity as Axsome slips on mixed Alzheimer’s studies
Shares of Axsome Therapeutics (AXSM) are under pressure on Monday after the company reported mixed results for a pair of studies of its ...
Axsome to seek approval for Alzheimer's-related agitation drug despite mixed data
Axsome Therapeutics said on Monday its experimental treatment for the Alzheimer's disease-related agitation met the main goal of a late-stage trial.
Seeking Alpha8d
Axsome reports mixed results for Alzheimer's agitation drug
Axsome (AXSM) said the results support the efficacy and safety of AXS-05 in the treatment of agitation in Alzheimer's patients. The company plans to submit a New Drug Application to the FDA for ...